CIBUS INC (CBUS) Stock Price & Overview
NASDAQ:CBUS • US17166A1016
Current stock price
The current stock price of CBUS is 1.5 USD. Today CBUS is up by 3.45%. In the past month the price decreased by -29.58%. In the past year, price decreased by -22.28%.
CBUS Key Statistics
- Market Cap
- 114.255M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.38
- Dividend Yield
- N/A
CBUS Stock Performance
CBUS Stock Chart
CBUS Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to CBUS. When comparing the yearly performance of all stocks, CBUS is a bad performer in the overall market: 83.09% of all stocks are doing better.
CBUS Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to CBUS. CBUS may be in some trouble as it scores bad on both profitability and health.
CBUS Earnings
On March 17, 2026 CBUS reported an EPS of -0.59 and a revenue of 1.06M. The company missed EPS expectations (-34.52% surprise) and missed revenue expectations (-36.97% surprise).
CBUS Forecast & Estimates
9 analysts have analysed CBUS and the average price target is 14.96 USD. This implies a price increase of 897.33% is expected in the next year compared to the current price of 1.5.
For the next year, analysts expect an EPS growth of 50.71% and a revenue growth 87.43% for CBUS
CBUS Groups
Sector & Classification
CBUS Financial Highlights
Over the last trailing twelve months CBUS reported a non-GAAP Earnings per Share(EPS) of -2.38. The EPS increased by 22.48% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -41.66% | ||
| ROE | -582.18% | ||
| Debt/Equity | 10.77 |
CBUS Ownership
CBUS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.4 | 351.47B | ||
| AMGN | AMGEN INC | 15.09 | 185.95B | ||
| GILD | GILEAD SCIENCES INC | 14.75 | 161.855B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.09 | 109.449B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.03 | 79.456B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.76 | 40.768B | ||
| INSM | INSMED INC | N/A | 29.176B | ||
| NTRA | NATERA INC | N/A | 28.878B | ||
| BIIB | BIOGEN INC | 11.44 | 27.06B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 26.812B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.41 | 24.859B | ||
| MRNA | MODERNA INC | N/A | 20.119B | ||
| INCY | INCYTE CORP | 12.23 | 18.836B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CBUS
Company Profile
Cibus, Inc. engages in the research and development of plant traits to seed companies for royalties. The company is headquartered in San Diego, California. The company went IPO on 2017-07-20. Its business is the development of plant traits for some of the agricultural food crops that help address specific productivity, profitability, sustainability, or yield challenges in farming. Its core technology propriety gene editing platform is called the Rapid Trait Development System (RTDS). The company is the underlying technology in the Company's Trait Machine process, an end-to-end semi-automated high-throughput gene editing system that directly edits seed companies' elite germplasm. The company has a pipeline of five productivity traits. The company has developed the productivity trait Pod Shatter Reduction (PSR) in Canola and Winter Oilseed Rape (WOSR) strengthens the sheath around the canola seeds. Its advanced productivity traits, Sclerotinia resistance and HT2 in Canola and WOSR, continue to progress and offer white mold disease resistance and broadleaf weed herbicide tolerance.
Company Info
IPO: 2017-07-20
CIBUS INC
6455 Nancy Ridge Drive
San Diego CALIFORNIA US
Employees: 118
Phone: 18584500008
CIBUS INC / CBUS FAQ
Can you describe the business of CIBUS INC?
Cibus, Inc. engages in the research and development of plant traits to seed companies for royalties. The company is headquartered in San Diego, California. The company went IPO on 2017-07-20. Its business is the development of plant traits for some of the agricultural food crops that help address specific productivity, profitability, sustainability, or yield challenges in farming. Its core technology propriety gene editing platform is called the Rapid Trait Development System (RTDS). The company is the underlying technology in the Company's Trait Machine process, an end-to-end semi-automated high-throughput gene editing system that directly edits seed companies' elite germplasm. The company has a pipeline of five productivity traits. The company has developed the productivity trait Pod Shatter Reduction (PSR) in Canola and Winter Oilseed Rape (WOSR) strengthens the sheath around the canola seeds. Its advanced productivity traits, Sclerotinia resistance and HT2 in Canola and WOSR, continue to progress and offer white mold disease resistance and broadleaf weed herbicide tolerance.
What is the stock price of CIBUS INC today?
The current stock price of CBUS is 1.5 USD. The price increased by 3.45% in the last trading session.
Does CBUS stock pay dividends?
CBUS does not pay a dividend.
What is the ChartMill technical and fundamental rating of CBUS stock?
CBUS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the market capitalization of CBUS stock?
CIBUS INC (CBUS) has a market capitalization of 114.25M USD. This makes CBUS a Micro Cap stock.
When does CIBUS INC (CBUS) report earnings?
CIBUS INC (CBUS) will report earnings on 2026-05-07.